Vimarsana
Biggest News Aggregation in the World

Page 16 - First Author News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from First Author. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In First Author Today - Breaking & Trending Today

Mice study shows how working memory is maintained across interconnected brain regions - Vimarsana News

Mice study shows how working memory is maintained across interconnected brain regions

How does the brain keep in mind a phone number before dialing? Working memory is an essential component of cognition, allowing the brain to remember information temporarily and use it to guide future behavior.

TfL advertising policy restricting the advertisement of junk foods could save lives and NHS money - Vimarsana News

TfL advertising policy restricting the advertisement of junk foods could save lives and NHS money

Junk food advertising restrictions on Transport for London (TfL) networks have prevented almost 100,000 obesity cases and is expected to save the NHS over £200 million, according to new research.

Researchers develop new lab-based model of the heart and circulatory system - Vimarsana News

Researchers develop new lab-based model of the heart and circulatory system

Researchers from RCSI University of Medicine and Health Sciences have developed a new lab-based model of a heart and circulatory system that will help test devices to treat patients with one of the most common forms of heart failure.

Researchers identify the role of TREM2-positive macrophages in non-alcoholic fatty liver disease - Vimarsana News

Researchers identify the role of TREM2-positive macrophages in non-alcoholic fatty liver disease

A MedUni Vienna study team has identified the role of a specific subtype of macrophages (white blood cells) in progressive non-alcoholic fatty liver disease.

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers - Vimarsana News

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers

Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Solid Tumors Patients Receiving a Dose...